- GSK walks away from Alector pact as immuno-neurology bet fizzlesAfter two high-profile trial failures over the past year, GSK is breaking off a deal that features $700 million upfront that it signed with Alector for neurodegenerative disease treatments. GSK’s…Endpoints · 18d ago↗ source
- STAT+: 931 days. The drug approval scandal hiding in plain sightTwo years, six months, and 18 days have elapsed since Northwest Biotherapeutics submitted its brain cancer treatment for regulatory approval.STAT · 18d ago↗ source
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drugAstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drugmakers.STAT